Evidence map›Paper›PMID 26276155›Full record

ArticleMolecular imaging and biology2016

Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.

Narges K Tafreshi, Mark C Lloyd, Joshua B Proemsey, Marilyn M Bui, Jongphil Kim, Robert J Gillies, David L Morse

Open access · greenAbstract read
In one paragraph

Article in Molecular imaging and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Prospective pilot study with [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  3. Tumor Hypoxia: How Conventional Histology Is Reshaped in Breast Carcinoma.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Preclinical Characterization of DPI-4452: AJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Cancer heterogeneity and metastasis: life at the edge.Clinical & experimental metastasis · 2022
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Narges K TafreshiDepartment of Cancer Imaging & Metabolism, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Mark C LloydAnalytic Microscopy Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Joshua B ProemseyAnalytic Microscopy Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Marilyn M BuiAnalytic Microscopy Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Jongphil KimDepartment of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Robert J GilliesDepartment of Cancer Imaging & Metabolism, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
David L MorseDepartment of Cancer Imaging & Metabolism, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA. david.morse@moffitt.org.
Moffitt Cancer Center · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
"Research Supplement to Promote Diversity in Health-Related Research", as part of Moffitt PS-OC, "Cancer as a Complex adaptive System"U54CA193489 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ANDERSON, ALEXANDER ROBERTSON ALLAN, GATENBY, ROBERT A · 2015 to 2020
$12.5M
Causes & Consequences of Acid pH in TumorsR01CA077575 · NCI · UNIVERSITY OF ARIZONA · PI GILLIES, ROBERT J. · 1999 to 2018
$8.5M
Integrative Molecular Epidemiology WorkshopR25CA174664 · NCI · AMERICAN ASSOCIATION FOR CANCER RESEARCH · PI Shelley S Tworoger · 2013 to 2026
$2.8M
NCI NIH HHS NIH/NCI R01CA077575NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA077575NCI NIH HHS R25 CA174664NCI NIH HHS U54 CA193489
6 · The paper itself

Abstract

purposeHypoxia is commonly observed in regions of primary tumors and metastases, and is associated with resistance to treatment, more aggressive tumor phenotypes and poor prognosis. Reliable and validated imaging biomarkers of hypoxia are needed for pre-clinical studies and clinical use. Expression of cell-surface carbonic anhydrases IX and XII (CAIX and CAXII) in tumor cells has been associated with tumor hypoxia. CAIX and CAXII specific antibodies conjugated to fluorescent dye were evaluated for the non-invasive detection of hypoxia in vivo. PROCEDURES: Human breast cancer cell lines (MCF10A, DCIS, MCF7, ZR-75.1 and MDA-mb231) were characterized for CAIX and CAXII expression by real-time RT-PCR and immunocytochemistry (ICC) under normoxic and hypoxic conditions. Immunohistochemical (IHC) staining of CAIX, CAXII and the commercially available exogenous hypoxia marker, pimonidazole, was performed using sections of ZR-75.1 and MDA-mb-231 orthotopic breast cancer xenograft tumors from nude mice. In vivo fluorescence imaging of ZR-75.1 tumors in animals housed at varied levels of oxygen was used to quantify the relative uptake of the CAIX and CAXII agents and a commercially available sulfonamide-based agent. Corresponding tumor sections were IHC stained for CAIX, CAXII and pimonidazole.

resultsCAIX mRNA expression was significantly higher (p < 0.05) in hypoxia for all cell lines, which was in agreement with protein expression by ICC. CAXII expression was mixed, with a modest hypoxia-related increase in two cell lines (p < 0.05) and no change in others. Quantified IHC staining of ZR-75.1 and MDA-mb-231 tumor sections showed that CAIX and CAXII expression was elevated in regions with pimonidazole staining, but CAXII levels were lower than CAIX. Tumor uptake of the CAIX targeted agent, and IHC staining of CAIX and pimonidazole in corresponding tumor sections were correlated, and co-registered, and shown to be significantly elevated by level of oxygenation (p < 0.001): hypoxia > normoxia > hyperoxia. However, the CAXII and sulfonamide agents were not significantly correlated with hypoxia.

conclusionThese studies suggest that the fluorescently labeled CAIX-specific agent is a more robust indicator of hypoxia in vivo compared to the CAXII-specific agent or the agent specific to the CA active site.

Indexed as

Analysis of VarianceAnimalsAntigens, NeoplasmBiomarkers, TumorBreast NeoplasmsCarbonic Anhydrase IXCarbonic AnhydrasesCell Line, TumorFemaleFluorescenceGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHumansMice, NudeMolecular ImagingOxygenAntigens, NeoplasmBiomarkers, TumorCA9 protein, humanCarbonic Anhydrase IXCarbonic Anhydrasescarbonic anhydrase XIIOxygenRNA, MessengerBreast cancerCarbonic anhydrase IXCarbonic anhydrase XIINon-invasive imaging of hypoxiaTargeted agents

Identifiers

PMID26276155
PMCPMC4754166
OpenAlexW1198225926

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.